{"generic":"Disopyramide Phosphate","drugs":["Disopyramide Phosphate","Norpace","Norpace CR"],"mono":[{"id":"184330-s-0","title":"Generic Names","mono":"Disopyramide Phosphate"},{"id":"184330-s-1","title":"Dosing and Indications","sub":[{"id":"184330-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Ventricular arrhythmia, Life-threatening:<\/b> rapid control, immediate-release, patients greater than 50 kg, 300 mg ORALLY followed by appropriate maintenance dose<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> rapid control, immediate-release, patients less than 50 kg, 200 mg ORALLY followed by appropriate maintenance dose<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> maintenance, 400 to 800 mg\/day ORALLY (divided every 6 hr for immediate-release formulation or every 12 hr for controlled-release formulation); controlled-release formulation is not recommended for initial therapy<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> patients less than 50 kg, 400 mg\/day ORALLY (divided doses)<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> MAX dose, 1200 to 1600 mg\/day ORALLY<\/li><\/ul>"},{"id":"184330-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Ventricular arrhythmia, Life-threatening:<\/b> less than 1 yr old, 10 to 30 mg\/kg\/day ORALLY (divide every 6 hr)<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> 1 to 4 yr old, 10 to 20 mg\/kg\/day ORALLY (divide every 6 hr)<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> 4 to 12 yr old, 10 to 15 mg\/kg\/day ORALLY (divide every 6 hr)<\/li><li><b>Ventricular arrhythmia, Life-threatening:<\/b> 12 to 18 yr old, 6 to 15 mg\/kg\/day ORALLY (divide every 6 hr)<\/li><\/ul>"},{"id":"184330-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>cardiomyopathy\/cardiac decompensation (immediate-release):<\/b> NO loading dose<\/li><li><b>cardiomyopathy\/cardiac decompensation (immediate-release):<\/b> 100 mg ORALLY every 6-8 hr<\/li><li><b>hemodialysis:<\/b> a maintenance dose following hemodialysis sessions is recommended<\/li><li><b>liver disease:<\/b> 400 mg\/day ORALLY (divided doses)<\/li><li><b>renal impairment:<\/b> CrCl greater than 40 mL\/min, 400 mg\/day ORALLY (divided doses)<\/li><li><b>renal impairment:<\/b> CrCl less than 40 mL\/min, loading dose of 150 mg ORALLY immediate-release form may be given<\/li><li><b>renal impairment:<\/b> use of controlled-release form not recommended<\/li><li><b>renal impairment (immediate-release):<\/b> CrCl 30-40 mL\/min, 100 mg ORALLY every 8 hr<\/li><li><b>renal impairment (immediate-release):<\/b> CrCl 15-30 mL\/min, 100 mg ORALLY every 12 hr<\/li><li><b>renal impairment (immediate-release):<\/b> CrCl less than 15 mL\/min, 100 mg ORALLY every 24 hr<\/li><\/ul>"},{"id":"184330-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Ventricular arrhythmia, Life-threatening<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Supraventricular arrhythmia<br\/>"}]},{"id":"184330-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule; Capsule, Extended Release)<\/b><br\/>Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.<br\/>"},{"id":"184330-s-3","title":"Contraindications\/Warnings","sub":[{"id":"184330-s-3-9","title":"Contraindications","mono":"<ul><li>cardiogenic shock<\/li><li>congenital QT prolongation<\/li><li>hypersensitivity to disopyramide<\/li><li>second or third degree AV block<\/li><\/ul>"},{"id":"184330-s-3-10","title":"Precautions","mono":"<ul><li>congestive heart failure<\/li><li>digitalization to be used in patients with atrial fibrillation or flutter prior to disopyramide<\/li><li>dosage reductions or withdrawal if heart block develops<\/li><li>ECG abnormalities (ie, QRS widening \/QT\/QTc prolongation)<\/li><li>electrolyte abnormalities (ie, hypokalemia\/hyperkalemia)<\/li><li>geriatrics<\/li><li>glaucoma<\/li><li>hypoglycemia<\/li><li>liver disease<\/li><li>myasthenia gravis<\/li><li>renal impairment<\/li><li>sick sinus syndrome\/ Wolff-Parkinson-White syndrome\/bundle branch block<\/li><li>urinary retention (including benign prostatic hypertrophy)<\/li><\/ul>"},{"id":"184330-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Disopyramide: C (FDA)<\/li><li>Disopyramide: B2 (AUS)<\/li><\/ul>"},{"id":"184330-s-3-12","title":"Breast Feeding","mono":"<ul><li>Disopyramide: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Disopyramide: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"184330-s-4","title":"Drug Interactions","sub":[{"id":"184330-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"184330-s-4-14","title":"Major","mono":"<ul><li>Ajmaline (probable)<\/li><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (probable)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (probable)<\/li><li>Azithromycin (probable)<\/li><li>Bedaquiline (theoretical)<\/li><li>Betaxolol (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (probable)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (probable)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dofetilide (probable)<\/li><li>Dolasetron (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Erythromycin (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (probable)<\/li><li>Haloperidol (probable)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (probable)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (probable)<\/li><li>Imipramine (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidocaine (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nalidixic Acid (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (probable)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pirmenol (probable)<\/li><li>Prilocaine (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (probable)<\/li><li>Salmeterol (theoretical)<\/li><li>Sertindole (probable)<\/li><li>Sevoflurane (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (probable)<\/li><li>Sultopride (probable)<\/li><li>Sunitinib (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (probable)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (probable)<\/li><\/ul>"},{"id":"184330-s-4-15","title":"Moderate","mono":"<ul><li>Atenolol (probable)<\/li><li>Dalfopristin (probable)<\/li><li>Digoxin (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Nevirapine (probable)<\/li><li>Phenytoin (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinupristin (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"184330-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Negative inotropic effect on myocardium<\/li><li><b>Gastrointestinal:<\/b>Constipation (11%), Nausea (3% to 9%), Xerostomia (32%)<\/li><li><b>Musculoskeletal:<\/b>Muscle weakness<\/li><li><b>Ophthalmic:<\/b>Blurred vision (3% to 9%)<\/li><li><b>Renal:<\/b>Delay when starting to pass urine (14% to 23%), Urinary retention (3% to 9%)<\/li><li><b>Other:<\/b>Generalized aches and pains (3% to 9%), Malaise and fatigue (3% to 9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure, Heart block, Hypotension, Prolonged QT interval, Torsades de pointes<\/li><li><b>Endocrine metabolic:<\/b>Hypoglycemia (rare)<\/li><li><b>Hematologic:<\/b>Agranulocytosis (rare), Thrombocytopenia (rare)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity (rare)<\/li><\/ul>"},{"id":"184330-s-6","title":"Drug Name Info","sub":{"0":{"id":"184330-s-6-17","title":"US Trade Names","mono":"<ul><li>Norpace<\/li><li>Norpace CR<\/li><\/ul>"},"2":{"id":"184330-s-6-19","title":"Class","mono":"Antiarrhythmic, Group IA<br\/>"},"3":{"id":"184330-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"184330-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"184330-s-7","title":"Mechanism Of Action","mono":"Disopyramide phosphate is a type 1 anti-arrhythmic drug that decreases rate of diastolic depolarization (phase 4) in cells with augmented automaticity, the upstroke velocity (phase 0), and the disparity in refractoriness between adjacent normally perfused and infarcted myocardium. It also increases the action potential duration of normal cardiac cells and has no effect on alpha- or beta-adrenergic receptors.<br\/>"},{"id":"184330-s-8","title":"Pharmacokinetics","sub":[{"id":"184330-s-8-23","title":"Absorption","mono":"<ul><li>Oral, controlled-release: time to peak concentration, 4.9 h +\/- 1.4 h<\/li><li>Oral, extended-release: time to peak concentration, 5.58 h +\/- 1.44 h<\/li><li>Oral, immediate-release: time to peak concentration, 2 h<\/li><li>Oral, moderate heart failure: time to peak concentration, 2.3 h +\/- 1.5 h<\/li><\/ul>"},{"id":"184330-s-8-24","title":"Distribution","mono":"Protein binding: 50% to 65% <br\/>"},{"id":"184330-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; P450 CYP3A4<\/li><li>Metabolite: mono-N-dealkylated<\/li><\/ul>"},{"id":"184330-s-8-26","title":"Excretion","mono":"Renal: 50% unchanged, 20% as metabolite <br\/>"},{"id":"184330-s-8-27","title":"Elimination Half Life","mono":"<ul><li>6.7 h (4 h to 10 h)<\/li><li>(controlled-release), 11.65 h +\/- 4.72 h<\/li><li>(immediate-release), 8.31 h +\/- 1.83 h<\/li><li>impaired renal function: 8 h to 18 h<\/li><li>impaired hepatic function: prolonged <\/li><li>left ventricular dysfunction: 7.8 h +\/- 1.9 h (5 h to 9.5 h)<\/li><li>IV, moderate heart failure: 9.7 h +\/- 4.2 h (4.4 h to 7.8 h)<\/li><\/ul>"}]},{"id":"184330-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>(extended-release capsule) do not use extended-release capsules to prepare pediatric suspension<\/li><li>(pediatric) can prepare 1 mg\/mL to 10 mg\/mL suspension by adding entire contents of capsule to cherry syrup and dispensed in amber glass bottle and refrigerated; shake well before measuring dose<\/li><li>do not administer within 48 h before or 24 h after verapamil administration<\/li><\/ul>"},{"id":"184330-s-10","title":"Monitoring","mono":"<ul><li>ECG, blood pressure, heart rate, signs and symptoms of cardiac failure<\/li><li>liver and renal function<\/li><li>patients with congestive heart failure, chronic malnutrition, hepatic, renal, or other diseases: blood glucose<\/li><\/ul>"},{"id":"184330-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Capsule: 100 MG, 150 MG<br\/><\/li><li><b>Norpace CR<\/b><br\/>Oral Capsule, Extended Release: 100 MG, 150 MG<br\/><\/li><li><b>Norpace<\/b><br\/>Oral Capsule: 100 MG, 150 MG<br\/><\/li><\/ul>"},{"id":"184330-s-12","title":"Toxicology","sub":[{"id":"184330-s-12-31","title":"Clinical Effects","mono":"<b>DISOPYRAMIDE<\/b><br\/>OVERDOSE: Pronounced cardiovascular and anti-muscarinic effects can occur in overdose. Severe effects of overdose can include: apnea, loss of consciousness, cardiac arrest, depression of atrial, atrioventricular and ventricular conduction, dysrhythmias, hypotension, heart failure, pulmonary edema, syncope, paresthesia and coma. Anticholinergic effects and heart failure may be more pronounced than quinidine and procainamide. ADVERSE EFFECTS: Some individuals with a history of prolonged QT interval may be at risk for developing torsades with therapy. Cases of severe hypoglycemia have occurred following therapeutic use.<br\/>"},{"id":"184330-s-12-32","title":"Treatment","mono":"<b>DISOPYRAMIDE <\/b><br\/><ul><li>Decontamination: Activated charcoal; gastric lavage if recent, large ingestion.<\/li><li>Ventricular arrhythmia: Obtain an ECG, institute continuous cardiac monitoring and administer oxygen. Evaluate for hypoxia, acidosis, and electrolyte disorders (particularly hypokalemia, hypocalcemia, and hypomagnesemia). Sodium bicarbonate is generally first line therapy for QRS widening and ventricular dysrhythmias, administer 1 to 2 mEq\/kg, repeat as needed to maintain blood pH between 7.45 and 7.55. In patients unresponsive to bicarbonate, consider lidocaine.<\/li><li>Torsades de pointes: Magnesium sulfate, overdrive pacing, and correct electrolyte abnormalities. Avoid class Ia antidysrhythmics and most class III antiarrhythmic which may further prolong QT internal and have been associated with torsades de pointes.<\/li><li>Bradycardia: Temporary pacemaker (first choice), atropine.<\/li><li>Hypotensive episode: IV 0.9% NaCl at 10 to 20 mL\/kg, dopamine or norepinephrine.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Monitoring of patient: Obtain serial ECGs and continuous cardiac monitoring. Monitor vital signs, ABGs and respiratory function as indicated in patients with respiratory depression, severe dysrhythmias, hypotension or pulmonary edema. Obtain a chest x-ray following significant exposure or pulmonary symptoms.<\/li><li>Hemodialysis: Hemodialysis is not expected to be effective in the removal of disopyramide.<\/li><\/ul>"},{"id":"184330-s-12-33","title":"Range of Toxicity","mono":"<b>DISOPYRAMIDE<\/b><br\/>TOXICITY: Disopyramide doses up to 1600 mg\/day (given in divided doses) were tolerated in a limited number of patients with severe refractory ventricular tachycardia. In one case series, doses of 1.5 g were toxic in young adults following intentional misuse. Based on a small number of cases, doses of 2.5 g have caused severe toxicity. A teenage female survived an intentional overdose of 2.0 grams following intensive therapy for sustained electromechanical dissociation. THERAPEUTIC DOSE: ADULT: 400 to 800 mg\/day in divided doses. PEDIATRIC: 1 to 4 years: 10 to 20 mg\/kg\/day; 4 to 12 years: 10 to 15 mg\/kg\/day. <br\/>"}]},{"id":"184330-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position to minimize dizziness.<\/li><li>This drug may cause anticholinergic effects, especially xerostomia, urinary hesitancy, and constipation.<\/li><li>Instruct patient to report signs\/symptoms of cardiac failure or dysrhythmia.<\/li><li>Tell patient to report worsening depression, hallucinations, or unusual changes in behavior.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>Tell patient to not drink alcohol while taking this drug.<\/li><li>Patient should not take this drug within 48 h before or 24 h after verapamil administration.<\/li><\/ul>"}]}